CLINICAL_TRIALS
trial_result
· 2015-10-14
Clinical Trial Update: A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects [Phase 2]
Summary
A Phase 2 multiple ascending-dose study of daclatasvir (BMS-790052) in hepatitis C genotype 1–infected subjects has completed, with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2015-10-14